1. Home
  2. ELA vs NKTR Comparison

ELA vs NKTR Comparison

Compare ELA & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELA
  • NKTR
  • Stock Information
  • Founded
  • ELA 1965
  • NKTR 1990
  • Country
  • ELA United States
  • NKTR United States
  • Employees
  • ELA N/A
  • NKTR N/A
  • Industry
  • ELA Consumer Specialties
  • NKTR Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELA Consumer Discretionary
  • NKTR Health Care
  • Exchange
  • ELA Nasdaq
  • NKTR Nasdaq
  • Market Cap
  • ELA 175.2M
  • NKTR 160.4M
  • IPO Year
  • ELA N/A
  • NKTR 1994
  • Fundamental
  • Price
  • ELA $6.39
  • NKTR $0.64
  • Analyst Decision
  • ELA Strong Buy
  • NKTR Strong Buy
  • Analyst Count
  • ELA 1
  • NKTR 5
  • Target Price
  • ELA $7.00
  • NKTR $5.50
  • AVG Volume (30 Days)
  • ELA 20.5K
  • NKTR 1.6M
  • Earning Date
  • ELA 03-26-2025
  • NKTR 03-12-2025
  • Dividend Yield
  • ELA N/A
  • NKTR N/A
  • EPS Growth
  • ELA N/A
  • NKTR N/A
  • EPS
  • ELA 0.26
  • NKTR N/A
  • Revenue
  • ELA $180,376,229.00
  • NKTR $98,427,000.00
  • Revenue This Year
  • ELA $1.61
  • NKTR N/A
  • Revenue Next Year
  • ELA $6.30
  • NKTR N/A
  • P/E Ratio
  • ELA $24.76
  • NKTR N/A
  • Revenue Growth
  • ELA 2.92
  • NKTR 9.21
  • 52 Week Low
  • ELA $4.20
  • NKTR $0.64
  • 52 Week High
  • ELA $7.88
  • NKTR $1.93
  • Technical
  • Relative Strength Index (RSI)
  • ELA 58.35
  • NKTR 28.50
  • Support Level
  • ELA $5.43
  • NKTR $0.84
  • Resistance Level
  • ELA $6.66
  • NKTR $0.92
  • Average True Range (ATR)
  • ELA 0.28
  • NKTR 0.08
  • MACD
  • ELA 0.15
  • NKTR -0.02
  • Stochastic Oscillator
  • ELA 82.69
  • NKTR 0.00

About ELA Envela Corporation

Envela Corp and its subsidiaries engage in diverse business activities within the recommerce sector. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Share on Social Networks: